BiTE Immune Targeted Therapy in mCRPC – Tanya Dorff
Alicia Morgans and Tanya Dorff discuss the recent work on Bi-specific T-Cell antibody (BiTE) therapies. AMG160 is a half-life extended PSMA-targeted bispecific T-cell engager immune therapy for metastatic castration-resistant prostate cancer (mCRPC). Dr. Dorff describes BiTE therapies and the AMG 160 trial. She shares PSA responses seen in patients on BiTE therapy. Dr. Dorff discusses the…